How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

45,670 results for

Obesity Medication

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

45641. Obesity drug endorsed by NICE Full Text available with Trip Pro

Obesity drug endorsed by NICE 11250844 2001 04 12 2018 11 30 0959-8138 322 7287 2001 Mar 17 BMJ (Clinical research ed.) BMJ Obesity drug endorsed by NICE. 637 Wise J J eng News England BMJ 8900488 0959-8138 0 Anti-Obesity Agents 0 Enzyme Inhibitors 0 Lactones 95M8R751W8 Orlistat EC 3.1.1.3 Lipase AIM IM Anti-Obesity Agents therapeutic use Enzyme Inhibitors therapeutic use Humans Lactones therapeutic use Lipase antagonists & inhibitors Obesity drug therapy Orlistat Practice Guidelines as Topic

2001 BMJ : British Medical Journal

45642. Drug treatment for obesity : We need more studies in men at higher risk of coronary events Full Text available with Trip Pro

11573499 Adult Appetite Depressants therapeutic use Cardiovascular Diseases blood etiology prevention & control Cholesterol, LDL blood Cyclobutanes therapeutic use Female Humans Male Obesity blood complications drug therapy Randomized Controlled Trials as Topic Weight Loss 2001 6 9 10 0 2001 7 6 10 1 2001 6 9 10 0 ppublish 11397730 PMC1120461 N Engl J Med. 1996 Feb 8;334(6):374-81 8538710 Clin Pharmacol Ther. 1992 May;51(5):586-94 1587072 Lancet. 1989 Nov 11;2(8672):1142-5 2572857 Am J Med. 1984 Feb (...) Drug treatment for obesity : We need more studies in men at higher risk of coronary events 11397730 2001 07 05 2018 11 13 0959-8138 322 7299 2001 Jun 09 BMJ (Clinical research ed.) BMJ Drug treatment for obesity. We need more studies in men at higher risk of coronary events. 1379-80 Després J P JP eng Editorial Research Support, Non-U.S. Gov't England BMJ 8900488 0959-8138 0 Appetite Depressants 0 Cholesterol, LDL 0 Cyclobutanes WV5EC51866 sibutramine AIM IM BMJ. 2001 Sep 8;323(7312):576

2001 BMJ : British Medical Journal

45643. Drugs are not best for obesity Full Text available with Trip Pro

Drugs are not best for obesity 11573499 2001 09 27 2018 11 13 0959-8138 323 7312 2001 Sep 08 BMJ (Clinical research ed.) BMJ Drugs are not best for obesity. 576 Berry E M EM eng Comment Letter England BMJ 8900488 0959-8138 AIM IM BMJ. 2001 Jun 9;322(7299):1379-80 11397730 Humans Life Style Obesity therapy Patient Education as Topic 2001 9 28 10 0 2001 9 28 10 1 2001 9 28 10 0 ppublish 11573499 PMC1121151 Diabetes Care. 2001 Jan;24(1):117-23 11194216 BMJ. 2001 Jun 9;322(7299):1379-80 11397730 Am

2001 BMJ : British Medical Journal

45644. Obesity drug sibutramine (Meridia): hypertension and cardiac arrhythmias Full Text available with Trip Pro

Obesity drug sibutramine (Meridia): hypertension and cardiac arrhythmias 12041851 2002 06 21 2018 11 13 0820-3946 166 10 2002 May 14 CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne CMAJ Obesity drug sibutramine (Meridia): hypertension and cardiac arrhythmias. 1307-8 Wooltorton Eric E eng Journal Article Canada CMAJ 9711805 0820-3946 0 Appetite Depressants 0 Cyclobutanes WV5EC51866 sibutramine AIM IM Appetite Depressants adverse effects therapeutic use (...) Arrhythmias, Cardiac chemically induced Cyclobutanes adverse effects therapeutic use Humans Hypertension chemically induced Obesity drug therapy 2002 6 4 10 0 2002 6 22 10 1 2002 6 4 10 0 ppublish 12041851 PMC111085 Lancet. 2000 Dec 23-30;356(9248):2119-25 11191537 Arch Intern Med. 2000 Jul 24;160(14):2185-91 10904462 Int J Obes Relat Metab Disord. 2000 Feb;24(2):144-50 10702763 Diabetes Obes Metab. 2000 Jun;2(3):175-87 11220553 Obes Res. 1999 Jul;7(4):363-9 10440592 JAMA. 2001 Sep 19;286(11):1331-9

2002 CMAJ: Canadian Medical Association Journal

45645. Drug to treat obesity: editorial writer responds Full Text available with Trip Pro

Drug to treat obesity: editorial writer responds 9099162 1997 05 08 2013 11 21 0820-3946 156 7 1997 Apr 01 CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne CMAJ Drug to treat obesity: editorial writer responds. 978 Faich G A GA eng Comment Letter Canada CMAJ 9711805 0820-3946 0 Appetite Depressants 2DS058H2CF Fenfluramine AIM IM CMAJ. 1997 Mar 15;156(6):768-9 9084379 Appetite Depressants therapeutic use Conflict of Interest Fenfluramine therapeutic use (...) Humans Obesity drug therapy 1997 4 1 1997 4 1 0 1 1997 4 1 0 0 ppublish 9099162 PMC1227156

1997 CMAJ: Canadian Medical Association Journal

45646. Drug overdose--a hidden hazard of obesity. Full Text available with Trip Pro

Drug overdose--a hidden hazard of obesity. 3694619 1988 02 10 2018 11 13 0141-0768 80 11 1987 Nov Journal of the Royal Society of Medicine J R Soc Med Drug overdose--a hidden hazard of obesity. 708-9 Cox J J Oncology Unit, Bradford Royal Infirmary. Penn N N Masood M M Hancock A K AK Parker D D eng Case Reports Journal Article England J R Soc Med 7802879 0141-0768 5J49Q6B70F Vincristine 80168379AG Doxorubicin IM Adult Breast Neoplasms complications drug therapy Cardiomyopathy, Dilated chemically (...) induced Doxorubicin adverse effects pharmacokinetics therapeutic use Female Humans Obesity complications metabolism Vincristine therapeutic use 1987 11 1 1987 11 1 0 1 1987 11 1 0 0 ppublish 3694619 PMC1291097 Clin Pharmacol Ther. 1973 Jul-Aug;14(4):592-600 4723268 Cancer. 1974 Jan;33(1):19-27 4810094 Cancer. 1984 Mar 1;53(5):1042-8 6692298 Cancer. 1980 May 1;45(9):2231-9 7379023 Ann Intern Med. 1979 Nov;91(5):710-7 496103

1987 Journal of the Royal Society of Medicine

45647. A health-economic comparison of diet and drug treatment in obese men with mild hypertension. (Abstract)

A health-economic comparison of diet and drug treatment in obese men with mild hypertension. To compare dietary and antihypertensive drug treatment in obese men with mild hypertension in economic terms.A 6-week run-in period followed by randomization to either diet or drug treatment, lasting for 1 year. Blood pressure was measured blindly and serum lipid concentrations assessed at run-in and after 1 year. A computer-based model was used in five cost-effectiveness simulations with different (...) advertisement in newspaper). Exclusion criteria were diabetes mellitus, organ damage secondary to hypertension, and diseases that might have interfered with compliance and the interpretation of results. Sixty-one patients completed the study.Dietary treatment was based upon weight reduction and sodium restriction. Drug treatment used a stepped-care approach, with atenolol as the drug of first choice.Life years gained and willingness to pay.Drug treatment was the preferred option in three of the five cost

1992 Journal of hypertension Controlled trial quality: uncertain

45648. Ambulatory computer-assisted therapy for obesity: a new frontier for behavior therapy. (Abstract)

Ambulatory computer-assisted therapy for obesity: a new frontier for behavior therapy. 4056186 1985 12 20 2009 11 11 0022-006X 53 5 1985 Oct Journal of consulting and clinical psychology J Consult Clin Psychol Ambulatory computer-assisted therapy for obesity: a new frontier for behavior therapy. 698-703 Burnett K F KF Taylor C B CB Agras W S WS eng Clinical Trial Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't United States J Consult Clin Psychol 0136553 0022-006X (...) IM Adult Behavior Therapy instrumentation Computers Diet, Reducing psychology Feedback Female Humans Microcomputers Middle Aged Obesity therapy 1985 10 1 1985 10 1 0 1 1985 10 1 0 0 ppublish 4056186

1985 Journal of Consulting and Clinical Psychology Controlled trial quality: uncertain

45649. [Dietetic therapy of obesity. Preliminary considerations on the combined therapy with ursodeoxycholic acid in the prevention of cholesterol lithiasis]. (Abstract)

[Dietetic therapy of obesity. Preliminary considerations on the combined therapy with ursodeoxycholic acid in the prevention of cholesterol lithiasis]. The use of ursodeoxycholic acid (UDCA) was found useful in reducing the incidence of cholelithiasis (p < 0.05) without provoking any other alteration in hepatic function. This preliminary experience underlines the appropriateness of carrying out further studies on the utility of preventive treatment for the formation of cholesterol calculi (...) with biliary acids, and in particular UDCA, in obese subjects who are receiving dietary treatment. The protective action of ursodeoxycholic acid in the prevention of biliary lithiasis during the course of low-calorie diets was evaluated in 40 obese subjects (31 females, 9 males) treated for 4 months with fibre-rich (approximately 40 g/day) low-calorie diets of 900-1200 Kcal, of whom 20 received 450-750 mg of UDCA/day and 20 were treated with placebo.

1993 Minerva medica

45650. Children's attitudes and behavioral intentions toward a peer presented as obese: does a medical explanation for the obesity make a difference? (Abstract)

Children's attitudes and behavioral intentions toward a peer presented as obese: does a medical explanation for the obesity make a difference? To examine the effect of information on children's attitudes and behavioral intentions toward a peer presented as obese.Children (N = 184) were randomly assigned to observe a video of a boy or girl in one of three conditions: average-weight, obese, obese with medical information explaining the obesity. They rated stereotypical attitudes on the Adjective (...) Checklist and behavioral intentions on the Shared Activities Questionnaire (SAQ-B).Ratings were generally more favorable for the average-weight than for the obese condition. However, provision of medical information had a positive effect on attitudes toward the obese peer only for younger children and a negative effect on willingness of older children to share academic activities with the peer. Boys and girls showed more positive behavioral intentions toward the same-sex target child regardless

2000 Journal of pediatric psychology Controlled trial quality: uncertain

45651. Effect of anti-obesity drugs promoting energy expenditure, yohimbine and ephedrine, on gastric emptying in obese patients. (Abstract)

Effect of anti-obesity drugs promoting energy expenditure, yohimbine and ephedrine, on gastric emptying in obese patients. The effect of ephedrine, a non-selective adrenoreceptor agonist, and yohimbine, a selective alpha 2-adrenolytic drug, on gastric emptying of a radiolabelled solid meal was examined in groups of 8 (all women) and 15 (4 men and 11 women) obese patients, respectively. Patients were given orally, double-blind in random order, placebo or 50 mg ephedrine in the first group (...) of obesity.

1991 Alimentary pharmacology & therapeutics Controlled trial quality: uncertain

45652. Advanced Medical Therapy Versus Advanced Medical Therapy Plus Bariatric Surgery for the Resolution of Type 2 Diabetes

(Clinical Trial) Actual Enrollment : 150 participants Allocation: Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Treatment Official Title: STAMPEDE: Surgical Therapy And Medications Potentially Eradicate Diabetes Efficiently Study Start Date : February 2007 Actual Primary Completion Date : February 2016 Actual Study Completion Date : September 2016 Resource links provided by the National Library of Medicine related topics: related topics: Arms (...) Advanced Medical Therapy Versus Advanced Medical Therapy Plus Bariatric Surgery for the Resolution of Type 2 Diabetes Advanced Medical Therapy Versus Advanced Medical Therapy Plus Bariatric Surgery for the Resolution of Type 2 Diabetes - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number

2007 Clinical Trials

45653. Medical therapies and invasive treatments for coronary artery disease by body mass: the "obesity paradox" in the Get With The Guidelines database. (Abstract)

significantly younger but more likely to be men and have hypertension, diabetes, and hyperlipidemia. Unadjusted in-hospital mortality was highest in the underweight group (10.4%) and significantly lower in the healthy-weight (5.4%), overweight (3.1%), obese (2.4%), and extremely obese (2.9%) patients. Higher BMI was associated with increased use of standard medical therapies such as aspirin, beta blockers, inhibitors of the renin-angiotensin system, and lipid-lowering therapy in the hospital (...) Medical therapies and invasive treatments for coronary artery disease by body mass: the "obesity paradox" in the Get With The Guidelines database. Previous studies of hospitalized patients have suggested an "obesity paradox" with lower short-term mortality as weight increases. We hypothesized that some of this difference might be related to more aggressive management. To evaluate the effect of body mass index (BMI) on treatments and outcomes in patients with coronary artery disease (CAD

2007 American Journal of Cardiology

45654. Metabolic risk factors and the impact of medical therapy on the management of nephrolithiasis in obese patients. (Abstract)

Metabolic risk factors and the impact of medical therapy on the management of nephrolithiasis in obese patients. Previous studies have demonstrated that obesity can increase the risk of stone formation as well as recurrence rates of stone disease. Yet appropriate medical management can significantly decrease the risk of recurrent stone disease. Therefore, we analyzed our obese patient population, assessing the risk factors for stone formation and the impact of selective medical therapy (...) on recurrent stone formation.A retrospective chart review was performed to identify obese patients with stone disease from our Stone Center. Metabolic risk factors for stones were identified as well as patient response to medical therapy. A similar analysis was performed on a group of age and sex matched nonobese stone formers.Of 1,021 patients 140 (14%) were identified as obese (body mass index greater than 30). Of these patients complete metabolic evaluations were available in 83 with an average followup

2004 Journal of Urology

45655. Paying for costly pharmaceuticals: regulation of new drugs in Australia, England and New Zealand. (Abstract)

Paying for costly pharmaceuticals: regulation of new drugs in Australia, England and New Zealand. The United Kingdom, Australia and New Zealand use different criteria for public funding of pharmaceuticals, but all include estimates of clinical effectiveness and cost-effectiveness. Drug appraisal is done through the National Institute for Health and Clinical Excellence (NICE) in the UK, the Pharmaceutical Benefits Advisory Committee (PBAC) in Australia, and the Pharmaceutical Management Agency (...) (PHARMAC) in NZ. Of the 10 drugs deemed least cost-effective by NICE between 1996 and 2005, all were approved for funding in the UK, six were approved in Australia and five were approved in NZ. Australia and NZ refused funding for drugs for obesity, influenza and growth deficiency. All three countries made exceptions in order to fund drugs of poor cost-effectiveness for some "dread" diseases, but some drugs for less alarming conditions were either not funded or heavily restricted.

2008 Medical Journal of Australia

45656. [Comparative study of medical advice and cognitive-behavioral group therapy in the treatment of child-adolescent obesity]. (Abstract)

[Comparative study of medical advice and cognitive-behavioral group therapy in the treatment of child-adolescent obesity]. The aim of this study was to compare the efficacy of medical advice and cognitive-behavioral group therapy in the treatment of primary obesity in children and adolescents 7 to 15 years old.From five primary care centers 353 subjects (176 boys and 177 girls) were recruited and assigned to three groups. These groups were: medical advice (Group 1), cognitive-behavioral group (...) therapy (Group 2) and those that rejected all treatments (Group 3). Forty variables were controlled and studied for association with prognosis.A significant, but modest decrease in relative body mass index was noted in groups 1 and 2 in the first 6 months, but at two years no differences between the three groups were detected.It is concluded that cognitive-behavioral group therapy is not more effective than medical advice in our population and neither had a significant effect at two years when

1997 Anales españoles de pediatría

45657. Education, Counseling, and Drug Therapy to Reduce Symptoms of Metabolic Syndrome

Education, Counseling, and Drug Therapy to Reduce Symptoms of Metabolic Syndrome Education, Counseling, and Drug Therapy to Reduce Symptoms of Metabolic Syndrome - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding (...) more. Education, Counseling, and Drug Therapy to Reduce Symptoms of Metabolic Syndrome The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT00129792 Recruitment Status : Completed First Posted : August 12, 2005 Last Update Posted : October 29, 2014 Sponsor: Oregon Health and Science University

2005 Clinical Trials

45658. Caloric restriction versus drug therapy to delay the onset of aging diseases and extend life Full Text available with Trip Pro

Caloric restriction versus drug therapy to delay the onset of aging diseases and extend life There are two firmly established methods of prolonging life. Calorie restriction (CR) using nutrient-rich diets to prolong life in lower animals, and life saving medications in humans to delay the development of the major diseases of middle and old age. These two approaches have different mechanisms of action. In rats, CR at 40% below ad libitum intake begun soon after weaning and continued until death (...) that overlap with some of the mechanisms of CR in retarding these pathologies and thus may have similar antiaging and life prolonging actions. Such drugs may be regarded as CR mimetics which inhibit the development of certain life shortening diseases, without the need to lower calorie intake. In developed countries, better medical care, drug therapy, vaccinations, and other public health measures have extended human life by about 30 years during the 20th century without recourse to CR, which is so

2005 Age

45659. Cognitive behavioural therapy for weight gain associated with antipsychotic drugs. (Abstract)

Cognitive behavioural therapy for weight gain associated with antipsychotic drugs. Overweight and obesity are common concerns in individuals with severe mental disorders. In particular, antipsychotic drugs (AP) frequently induce weight gain. This phenomenon lacks current management and no previous controlled studies seem to use cognitive therapy to modify eating and weight-related cognitions. Moreover, none of these studies considered binge eating or eating and weight-related cognitions (...) as possible outcomes.The main aim of this study is to assess the effectivity of cognitive and behavioural treatment (CBT) on eating and weight-related cognitions, binge eating symptomatology and weight loss in patients who reported weight gain during AP treatment.A randomized controlled study (12-week CBT vs. Brief Nutritional Education) was carried out on 61 patients treated with an antipsychotic drug who reported weight gain following treatment. Binge eating symptomatology, eating and weight-related

2007 Schizophrenia research Controlled trial quality: uncertain

45660. Use of lifestyle changes treatment plans and drug therapy in controlling cardiovascular and metabolic risk factors. (Abstract)

Use of lifestyle changes treatment plans and drug therapy in controlling cardiovascular and metabolic risk factors. Intervention in weight management should begin before the onset of the metabolic syndrome. Therapeutic lifestyle changes (e.g., diet and physical activity) comprise the cornerstone of care for overweight and obese patients. Behavior modification approaches are useful in facilitating adherence to specific dietary regimens. Pharmacotherapy is an option for patients with a BMI >30 kg (...) /m(2) or for those with a BMI of 27 to 30 kg/m(2) and two or more risk factors, who have failed on diet and exercise alone. To date, the U.S. Food and Drug Administration has approved three weight loss agents: sibutramine, orlistat, and phentermine.

2006 Obesity

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>